Register Login

4D MOLECULAR THERAPEUTICS, INC. (FDMT)

SymbolFDMT
Name4D MOLECULAR THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address5858 HORTON STREET,SUITE 455, EMERYVILLE, California, 94608, United States
Telephone+1 510 505-2680
Fax—
Email—
Websitehttps://www.4dmoleculartherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001650648
Description

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Additional info from NASDAQ:
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

2026-05-07 20:10

(30% Negative) 4D MOLECULAR THERAPEUTICS, INC. (FDMT) Reports Q2 2026 Financial Results

Read more
2026-05-07 20:05

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

Read more
2026-05-07 17:58

New Form S-3 - 4D Molecular Therapeutics, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001193125-26-212323 <b>Size:</b> 902 KB

Read more
2026-04-28 17:07

New Form ARS - 4D Molecular Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001140361-26-017435 <b>Size:</b> 1 MB

Read more
2026-04-28 17:06

New Form DEF 14A - 4D Molecular Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001140361-26-017427 <b>Size:</b> 5 MB

Read more
2026-04-28 17:06

New Form DEFA14A - 4D Molecular Therapeutics, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001140361-26-017430 <b>Size:</b> 1 MB

Read more
2026-04-17 20:05

4DMT Announces New Employment Inducement Grants

Read more
2026-04-07 16:48

New Form SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001274173-26-000102 <b>Size:</b> 12 KB

Read more
2026-03-30 21:29

(99% Neutral) 4D MOLECULAR THERAPEUTICS, INC. (FDMT) Announces New Board Appointment

Read more
2026-03-27 20:30

Kirn David 🟢 acquired 750.0K shares (1 derivative) of 4D Molecular Therapeutics, Inc. (FDMT) at $9.88 ($7.4M) Transaction Date: Mar 25, 2026 | Filing ID: 129156

Read more